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Purpose: Primary open-angle glaucoma (POAG), which is the most common form of glaucoma, has been associated with
a heterogeneous genetic component. A genome-wide association study has identified a common sequence variant at 7q31
(rs4236601 [A]) near the caveolin genes in patients with POAG. Caveolins are a family of integral membrane proteins
which participate in many cellular processes, including vesicular transport, cholesterol homeostasis, signal transduction,
cell adhesion and migration. The goal of this study was to investigate the expression and regulation of caveolin 1
(CAV-1) and caveolin 2 (CAV-2) in normal and glaucoma trabecular meshwork (TM) cells.
Methods: CAV-1 and CAV-2 protein expression was quantified by immunoblot analysis using lysates isolated from
primary and immortalized TM cells or TM tissue dissected from normal and POAG eyes. The localization of caveolins
in TM cells was assessed by immunofluorescent microscopy. CAV-1 and CAV-2 protein expression was also investigated
in TM cells at various time points after subjecting the cells to known glaucomatous insults like dexamethasone (DEX)
and tumor growth factor beta2 (TGF-β2) treatment. Phosphorylation of CAV-1 at tyrosine 14 in normal and glaucoma
TM cell lines was evaluated using a specific monoclonal antibody (Ab). The 5′ upstream region of the CAV-1 gene was
amplified and the sequence variant rs4236601 (A/G polymorphic site) and several putative transcription factor-binding
sites were modified by in vitro mutagenesis. The effect of nucleotide sequence modifications in the CAV-1 upstream region
on gene expression was assayed in a luciferase-based system in TM and non-TM cells.
Results: CAV-1 and CAV-2 are expressed in TM cells, with localization to the cytoplasm and perinuclear region. DEX
increased CAV-1 expression in immortalized glaucoma TM cells by 2.8±0.1 (n=3) fold at 24 h and 2.5±0.1 (n=3) fold at
48 h, compared to 1.3±0.06 (n=3) fold at 24 and 48 h in immortalized normal TM cells. Phosphorylation of CAV-1 at
Tyr14 was reduced by 3.2±0.15 (n=3) fold in glaucomatous TM cells when compared to normal TM cells. In POAG and
normal TM tissue, CAV-1 expression was found to be uniform. CAV-2, on the other hand, was variable in independent
normal and glaucoma TM tissue. Substitution of a G for an A at base pair −2,388 upstream of the start codon of CAV-1,
corresponding to the minor allele rs4236601 [A], increased transcriptional activity in TM and non-TM cells when
compared to the native sequence. Deletion analysis of putative transcription factor binding sites in the CAV-1 promoter
region caused cell-specific effects on gene expression.
Conclusions: CAV-1 and CAV-2 are expressed in normal and glaucoma tissue and TM cell lines. Phosphorylation of
Tyr14 in CAV-1 and transcriptional regulation of CAV-1 expression may have a role in glaucomatous alterations in TM
cells.
Primary open angle glaucoma (POAG), which is the most
common form of glaucoma, is the second leading cause of
blindness worldwide, affecting nearly 70 million people [1].
POAG usually affects older people and, with the aging of
world populations, it is predicted that the number of patients
with  the  disease  will  substantially  increase  over  the  next
decade [2]. The prevalence of POAG among Americans aged
40  and  older  is  estimated  at  1.86  percent,  affecting  2.22
million individuals [3].
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The disease mainly affects the optic nerve and retinal
ganglion cells leading to visual impairment and blindness. Of
the  various  risk  factors  of  POAG,  elevated  intraocular
pressure (IOP) is the most prevalent and clinically relevant.
The  elevation  of  IOP  results  from  impaired  drainage  of
aqueous  humor  through  the  conventional  pathway,  which
consists of the trabecular meshwork (TM), Schlemm’s canal
(SC), collector channels and aqueous veins [3,4].
Recently, a genome-wide association study identified the
first common genetic risk factor for POAG, corresponding to
a region of the genome on chromosome 7q31 [5]. The locus
spans the caveolin 1 (CAV-1) and caveolin 2 (CAV-2) genes
and the minor allele of a genetic marker, rs4236601, located
in the noncoding upstream region of CAV-1, was found to be
tightly associated with POAG. However, a smaller population
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2878based study suggests that the rs4236601 polymorphic allele
may  not  be  a  universal  risk  factor  in  all  populations  [6].
Although the association does not mean that caveolins are
directly implicated in glaucoma, the finding has prompted
interest in caveolin family members and their role in cells of
the conventional outflow pathway.
Caveolins are the signature proteins of caveolae, flask-
shaped invaginations of plasma membrane that are 50–100
nanometers in diameter (reviewed in [7-9]). Caveolins are
scaffolding  proteins  with  molecular  weight  22–24  kDa
embedded in the cytosolic leaflet of cell membranes, with both
NH2-  and  COOH-termini  residing  in  the  cytosol  [10,11].
Caveolins  interact  with  and  compartmentalize  membrane-
localized signaling proteins to facilitate and modulate high-
fidelity  intracellular  signaling  pathways.  In  addition,  they
participate  in  many  important  cellular  processes  such  as
vesicular  transport  (including  cell  to  cell  protein  and
microRNA delivery), adhesion and cell motility, cholesterol
homeostasis and tumor suppression [7-9]. Caveolin structure,
function and role in human diseases have been extensively
investigated in different tissues and organs [9-13].
There are three caveolin proteins: CAV-1, CAV-2, and
caveolin 3 (CAV-3) [12-15] which form a structural backbone
of caveolae. CAV-1 and CAV-2 have overlapping patterns of
expression  throughout  numerous  tissues  [16,17],  whereas
CAV3 has more restricted expression in muscle [15,18] and
in the  nervous system [17].  CAV-1 and  CAV-2 genes are
located within 19 kilobases on human chromosome 7q31.1
(Figure 1), while CAV-3 is mapped to chromosome 3p25
[19].  Several  cell-type  specific  transcription  factor  (TF)
binding sites ensuring cell and tissue-specific expression have
been described in the caveolin promoter region [20-24]. Due
to the reported genetic association of a marker near CAV-1
and CAV-2 with POAG, we analyzed their expression and
regulation  in  normal  and  glaucomatous  TM  cells.
Additionally, we evaluated the role of cis-elements upstream
region of CAV-1 and the effect of the recently described G-A
polymorphism  located  in  the  upstream  region  of  CAV-1
(Figure 1) in transcriptional regulation.
METHODS
Normal and POAG TM tissue: TM tissues were dissected from
normal and POAG donor eyes. Tissues were placed in lysis
buffer (50 mM Tris pH 8.0, 0.5% sodium dodecyl sulfate,
0.5%  Triton-X100,  137  mM  NaCl,  3  mM  KCl,  8  mM
Na2HPO4-7H2O, 1 mM KH2PO4, protease inhibitors [Roche,
Indianapolis, IN]) [25] and homogenized using a Polytron
rotor stator homogenizer (Kinematica, Lucerne, Switzerland).
Supernatant was cleared of cellular debris by centrifugation
at 10,000× g for 5 min. Total protein concentration of cleared
Figure 1. Organization of the human CAV-1 and CAV-2 genes and localization of TF binding sites. A: Exon-intron structure of the caveolins
genes and localization of SNP rs4236601 marker (modified from [19]). The sizes of exons (white rectangular boxes) and the distance between
them (below Y) are shown. Marker rs4236601 is located 2,388 bp upstream from the start codon of CAV-1. B: localization of SNP and putative
TF binding sites (ovals) in the upstream region of CAV-1. Other details of TF-binding sites 1–8 are present in Table 2.The sequence of primers
used for the modifications of the fragment are presented in Table 1.
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2879lysates  was  estimated  using  a  Bradford  assay  (Bio-Rad,
Hercules, CA). Remaining lysate was stored at −80 °C until
further use.
Human TM cell culture: SV-40 transformed human normal
(NTM-5) and glaucoma (GTM-3) TM cell lines were derived
from normal and glaucoma donor eyes, respectively (generous
gifts  from  Dr.  Abbott  F.  Clark,  Alcon  Laboratories,  Fort
Worth, TX) [26,27]. The cells were cultured to confluence in
Dulbecco’s  Modified  Eagle’s  Medium  (DMEM,  Cat.  #
D5671; Sigma, St. Louis, MO) containing 4 mM glutamine
(Gibco,  Carlsbad,  CA),  10%  fetal  bovine  serum  (FBS;
Equitech  Bio,  Inc.,  Kerrville,  TX),  100  U  penicillin  and
100 μg/ml streptomycin (Cellgro, Manassas, VA). NTM-5
and GTM-3 cell cultures were maintained at 37 °C under a
humidified atmosphere of 5% CO2/95% air.
Primary cultures of TM cells (n=2) were established from
two separate donor eyes (a 20-year-old female and a 32-year-
old female) as described previously [28]. Briefly, TM was
dissected  and  digested  in  collagenase  A  (Worthington
Biochemical Corporation, Lakewood, NJ). The cells were
pelleted, resuspended in DMEM (Mediatech, Inc., Herndon,
VA), supplemented with 10% FBS and 100 U penicillin and
100 μg/ml streptomycin and placed in 6 well plates until the
cells were confluent. Cells from passages 3 to 7 were used for
the experiments.
Treatment of TM cells with DEX and TGF-β2: Confluent
NTM cells were serum-starved overnight and treated with
either 100 nM dexamethasone (DEX; Sigma) or transforming
growth factor beta 2 (TGF-β2; Sigma). Following treatment,
cells were collected at various time points and lysates prepared
as  described  previously  [29].  Briefly,  for  DEX  treatment,
10-7 M DEX was added to TM culture grown in serum free
media. Cells and CM were collected at 24 and 48 h and
proteins were separated on 12% SDS-PAGE gels. TGF-β2
was used at concentration 5 ng/ml.
Immunoblot analysis: Monoclonal mouse anti-CAV-1 (Cat.
#610406),  polyclonal  rabbit  Anti-CAV-1  (Cat.  #610059),
monoclonal mouse anti-phospho Tyr14-CAV-1 (pY14, Cat.
#  611338),  and  monoclonal  mouse  anti-CAV-2  (Cat.  #
610684; GE Healthcare Bio-Sciences Corp., Piscataway, NJ)
were  purchased  from  BD  Transduction  Laboratories  (San
Jose, CA). Actin monoclonal mouse Ab (Cat# MAB1501; GE
Healthcare Bio-Sciences Corp.) was obtained from Chemicon
International  (Temecula,  CA).  ECL  anti-mouse  IgG,
horseradish  peroxidase-linked  species-specific  whole  Ab
(Cat.  #NA931)  or  ECL  anti-rabbit  IgG,  horseradish
peroxidase-linked (Cat# RPN2108) were used as secondary
Abs  for  western  blot.  Goat  anti-rabbit  IgG-conjugated  by
AlexaFlor 488 (Invitrogen, Carlsbad, CA) was used for the
detection of CAV-1. Goat anti-mouse IgG Rhodamine Red-X
(Jackson  ImmunoResearch  Lab.,  West  Grove,  PA)
conjugated was used for CAV-2 detection.
Protein fractions (10 μg) from lysed cells or tissues were
resolved in 12% SDS-polyacrylamide gels and transferred
onto PVDF membranes. Blots were incubated in mouse anti-
Cav-1 and anti-Cav-2 primary Abs followed by the incubation
in  HRP-conjugated  secondary  antibody.  Enhanced
chemiluminescent  substrates  (ECL  Plus,  GE  Healthcare,
Piscataway, NJ) were used to visualize the bands. Differential
changes  in  caveolin  expression  were  calculated  by
densitometric  analysis  using  Kodak  Molecular  Imaging
software, (Woodbridge, CT) Version 4.5. Other details of
immunoblotting  are  described  previously  [30,31].  Briefly,
15-20  μg  of  total  protein  extract  were  loaded  on  a  12%
polyacrylamide  gel.  After  electrophoresis,  proteins  were
transferred  onto  0.45  μm  polyvinylidene  fluoride  (PVDF)
membrane (Millipore, Billerica, MA). Nonspecific binding
sites  were  blocked  by  immersing  the  membrane  in  a  5%
blocking reagent in Tris-buffered saline Tween (TBS-T) for
1 h. Membranes were washed, incubated with antibody, and
exposed to the film as described by the manufacturers of ECL
western blotting detection reagents (Amersham Pharmacia
Biotech, Piscataway, NJ). Fold change is represented by the
means±SEM from four independent experiments.
Immunofluorescent staining: NTM-5 and GTM-3 cells were
grown on coverslips coated with Poly-D-lysine. The cells
were  washed  with  cold  PBS  and  fixed  in  4%
paraformaldehyde  for  15  min  at  room  temperature.
Subsequently,  the  cells  were  washed  and  incubated  in
blocking buffer (3% BSA, 3% NGS, 0.1% triton X-100 in
PBS) for 2 h at room temperature. The coverslips were put in
respective primary Ab solutions overnight at 4 °C. Following
incubation, coverslips were washed with cold PBS and placed
in the appropriate secondary Ab for 1 h at room temperature.
Coverslips were washed with cold PBS and mounted on slides
with  Vectashield  containing  DAPI  (Vector  Laboratories,
Burlingame,  CA)  [32,33].  Images  were  digitally  captured
using  an  Olympus  1X71  inverted  microscope  (Olympus,
Waltham, MA), with 40× magnification.
Immunoprecipitation (IP): For CAV-1 IP, 4 μl of polyclonal
rabbit anti-CAV-1 with concentration 250 μg/ml from BD
Transduction Laboratories (San Jose, CA) was used. IP was
performed from cell extract containing 300 μg of total protein
using Protein A agarose beads as described in the ABCam
Immunoprecipitation Protocol. After IP, the samples were
dissolved  in  2×  loading  buffer,  separated  on  SDS-12%
polyacrylamide  gel,  transferred  to  PVDF  membrane  and
probed with monoclonal mouse anti-CAV-1(Cat. #610406) or
anti-phospho Tyrosine14-CAV-1 antibodies (Cat. # 611338)
both from BD Transduction Laboratories (San Jose, CA).
Generation of the CAV-1 upstream region: BAC clone RP11–
39K12 (Empire Genomics, Cedarhurst, NY) containing the
5′- upstream region of human CAV-1 was used as a template
for PCR [GC-rich PCR system (Roche, Indianapolis, IN)] to
generate  a  2,465  bp  upstream  region  of  CAV-1  (forward
primer 1 contained the KpnI site, reverse primer 2 contained
the SacI site, Table 1). The 2,465 bp fragment was purified
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2880using Zymo kit (Zymo Research Corporation, Irvine, CA),
digested with KpnI and SacI and inserted into the pGL3 basic
vector (Promega, Madison, WI). Sequence analysis of the
fragment revealed an A at position −2,388 upstream from the
CAV-1 start codon, representing the minor allele associated
with  POAG  [5].  This  construct  was  named  pGL3-
CAV-1promoterA.
In  vitro  mutagenesis  of  the  CAV-1  upstream  region:  To
generate the G variant at position −2,388, in vitro mutagenesis
using  the  Stratagene  “Quick  Change  Site-Directed
Mutagenesis  Kit”  (Cat.  200518;  Santa  Clara,  CA)  was
performed. Primers 3 and 4 (Table 1) were used to replace A
with G at position −2,388 upstream from the start codon in the
CAV-1 promoter region (Figure 1B; modification 1 in Table
2). Upstream region containing a G at position −2,388 was
inserted into pGL33-basic and the resulting construct was
called  pGL3-CAV-1promoterG.  The  effect  of  the  A-G
replacement, as well as the deletions of putative TF-binding
sites  shown  in  Figure  1B  (ovals)  and  in  Table  2  on  the
efficiency of gene expression was evaluated in TM cells from
glaucoma patient and control individuals. Since A in position
−2,388  from  the  start  codon  ATG  in  CAV-1  (GenBank
NG_012051.1; GI: 237820664) is a minor allele associated
with POAG, the results are presented in such a way that the
activity of the construct with G (pGL3-CAV-1promoterG) is
assigned 100% and the efficiency of the construct with A in
this  position  (pGL3-CAV-1promoterA)  is  used  for
comparison.
Deletions  of  putative  TF  binding  sites  from  the  CAV-1
upstream region: For deletions of putative TF binding sites
from the CAV-1 upstream region. a Stratagene “Quick Change
Site-Directed Mutagenesis Kit” (Cat. 200518; Santa Clara,
CA) was used following the manufacturer’s recommended
protocol. Table 1 shows the primer sequences used for the
deletions of putative TF binding sites (primers 5- 18). Other
details of the procedure have been described previously [34].
TABLE 1. PRIMERS USED FOR THE AMPLIFICATION AND IN VITRO MUTAGENESIS.
1 F 5′-TATAGGTACCAATTTATGGCAGTCATTA-3′ Amplification
2 R 5′-ATATGAGCTCGCTGGCCCGTGGCTGGAT-3′  
3 S 5′-GTCCTTTTCTAGTGTATTGTGTTTGTTAATATTTG-3′ A→G
4 Compl 5′-CAAATATTAACAAACACAATACACTAGAAAAGGAC-3′  
5 S 5′-GCTCCCACTAATGTGGTATTTAACTTTTGAAAGATCTTTAG-3′ NFκB (−1537)
6 Compl 5′-CTAAAGATCTTTCAAAAGTTAAATACCACATTAGTGGGAGC-3′  
7 S 5′-GCTTTAAATAATTCTACAATATTTTGTGTATTTTGC-3′ HNF-3
8 Compl 5′-GCAAAATACACAAAATATTGTAGAATTATTTAAAGC-3′  
9 S 5′-CAGAAAATATCGGTAATAAAAAAAGTTAAAGATCTTC-3′ Pou-IV
10 Compl 5′-GAAGATCTTTAACTTTTTTTATTACCGATATTTTCTG-3′  
11 S 5′-GGAGGCTCCCTCCCCCCCCTCCAGCGC-3′ Sp1 (−236)
12 Compl 5′-GCGCTGGAGGGGAGGGAGGGAGCCTCC-3′  
13 S 5′-GACCCGGCGCAGCACACCAACCGCGAGCAGAAC-3′ Ets
14 Compl - 5′-GTTCTGCTCGCGGTTGGTGTGCTGCGCCGGGTC-3′  
15 S 5′-CGCTGCGGGCGCTTGCTGCCAGAACCTTG-3′ Sp1 (−124)
16 Compl 5′-CAAGGTTCTGGCAGCAAGCGCCCGCAGCG-3′  
17 S 5′-CTTAAAGCACAGCCCATCACAGTTTTCATCCAGC-3′ NFκB (−40)
18 Compl 5′-GCTGGATGAAAACTGTGATGGGCTGTGCTTTAA-3′  
         1 and 2 - human CAV-1 promoter-specific primers used to amplify 2, 465 bp PCR product: forward primer containing Kpn1
         site and reversed primer containing SacI site. Three and 4 - primers used for the replacement of A on G in position −2,388
         upstream from the start codon in CAV-1 promoter region (Figure 1B, modification 1). Primers 5 – 18 used for the deletion of
         putative TF binding sites. Other details are presented in Methods and Table 2.
TABLE 2. MODIFIED SEQUENCES AND LOCALIZATION OF PUTATIVE TF-BINDING SITES IN THE 2,465 KILOBASE FRAGMENT USED IN LUC SYSTEM.
Modifications (substitutions or deletions) Location in the 2,465 base
pairs fragment
Names of putative TF-
binding site
Reference
1. G/A polymorphism (rs4236601) −2,388 MRF2, HNF1, HNF3 [5]
2. gggaaaatcc −1,537, −1,527 NFkB [21]
3. tataaac −889, −882 HNF-3/Fkh homolog1 [60]
4. attatag −807, −800 POU-IV [60]
5. ccccgccctc −236, −226 Sp1 [50]
6. cgtccggg −182, −174 Ets [24]
7. cagccaccg −124, −115 Sp1 [21]
8. gggaaacctcct −40, −28 NFkB [61]
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2881Briefly, the oligonucleotide primers, each complementary to
opposite  strands  of  the  vector,  were  extended  during
temperature  cycling  by  Pfu  Turbo  DNA  polymerase.  The
cycling was performed as follows: 95 °C, 2 min, followed by
18 cycles at 95 °C, 20 min, 60 °C , 10 min, 68 °C 4 min 5 s.
Finally the samples were incubated at 68 °C for 4 min. The
generated product was treated 15 min at 37 °C with Dpn I
endonuclease to digest the parental DNA template and to
select mutation-containing synthesized DNA.
Transient transfection and LUC assays: NTM-5 and GTM-3
cells were split into 24 well plates the day before transfection
at a density of 2×105 cells in 500 μl of DMEM with 10% FBS
without  antibiotics.  Transfection  was  performed  using
Lipofectamine  2000  (Invitrogen,  Carlsbad,  CA).  Briefly,
pGL3-CAV-1promoter was mixed with Lipofectamine at a
ratio of 1:2.5. pRL-SV40 containing the Renilla-Luc gene
(Promega, Madison, WI) was co-transfected to provide an
internal standard for transfection efficiency. After a 4–6 h
incubation, media containing lipofectamine and DNA was
removed and replaced with DMEM with 10% FBS. The cells
were incubated at 37 °C for 24 h, harvested and assayed for
firefly-Luc and Renilla-Luc activities using the DRL Luc
assay  system  (Promega,  Madison,  WI)  as  per  the
manufacturer’s  protocol.  Relative  light  units  (RLU)  were
determined using 100 µl of the appropriate substrate in a
BioTek  microplate  reader  (Synergy  H1;  Winooski,  VT)
Following normalization with Renilla-LUC activity, activity
of  pGL3-CAV-1  promoterG  was  assigned  100%  and  the
efficiency of the other constructs were used as comparisons.
The LUC values are expressed as percent change with each
vector. Each experiment was performed at least 3 times and
the results are represented as mean±SEM. The results were
analyzed by ANOVA (ANOVA).
RESULTS
CAV-1 and CAV-2 expression in TM cells from POAG patients
and  controls:  TM  cells  from  POAG  patients  and  control
individuals were used to compare the level of CAV-1 and
CAV-2. According to western blot analysis, CAV-1 is present
in TM from POAG patients and control samples in almost
equal amounts (Figure 2A), whereas for CAV-2 considerable
quantitative  variability  between  individuals  were  found
(Figure 2B). In addition higher molecular weight bands of
CAV-2 were found which have previously been identified as
hetero-oligomers containing CAV-1 and CAV-2 [35].
CAV-1 and CAV-2 expression and localization in TM cell
cultures:  CAV-1  and  CAV-2  were  found  to  have  similar
intracellular  localization  in  normal  (Figure  3A-C)  and
glaucomatous (Figure 3D-F) TM cells showing a perinuclear
punctuate appearance. CAV-1 expression was observed in the
cytoplasmic compartment (Figure 3, arrow), while CAV-2
appeared  to  be  bound  to  the  cell  membrane  (Figure  3B,
arrowheads).  In  both  cell  types,  there  was  extensive
colocalization of CAV-1 and CAV-2.
Effect of DEX on caveolin expression in TM cells: To analyze
CAV-1 expression in the presence of an agent that causes
glaucomatous insults by activating mechanisms relevant to
glaucoma pathogenicity, we treated immortalized NTM and
GTM cells with DEX [36,37]. In GTM-3 cells incubated with
100 nM DEX the level of CAV-1 expression increased 2.75
and 2.45 folds after 24 h and 48 h of incubation, respectively,
as compared to control (Figure 4A, lanes 5–8 and Figure 4C).
At the same time, the effect of DEX on the level of CAV-1
expression in NTM-5 cells was significantly less prominent
(1.3 fold increase after 24 h and 48 h of incubation (Figure
4A, lanes 1–4 and Figure 4B).
Figure 2. CAV-1 and CAV-2 in TM of
POAG  patients  and  controls.  Total
protein  (20  μg)  from  TM  cells  were
resolved  in  12%  SDS-polyacrylamide
gels,  transferred  on  PVDF  membrane
and probed with Abs to CAV-1 (A) and
CAV-2 (B). The amount of CAV-1 was
similar  both  in  POAG  patients  and
controls, whereas the CAV-2 was highly
variable  among  samples.
Heterooligomers CAV-1 – CAV-2 are
shown by arrowheads.
Molecular Vision 2011; 17:2878-2888 <http://www.molvis.org/molvis/v17/a312> © 2011 Molecular Vision
2882Tyrosine 14 phosphorylation in CAV-1: The localization and
functional  properties  of  CAV-1  are  modulated  by
phosphorylation of tyrosine-14 (Tyr14), which may alter its
trafficking and accumulation at focal adhesion [38-40]. In
GTM-3 cells, the level of Tyr14 phosphorylation (Figure 5B,
lane 4) was 3.2 times lower than in NTM-5 cells (Figure 5B,
lane 3), while the amount of non-phosphorylated CAV-1 was
equal (Figure 5A, lanes 1 and 2).
Effect of G/A polymorphism on expression: The effect of
transcription of the G/A variation at −2,388 upstream of the
CAV-1 transcription initiation site was examined in the LUC
system.
Following  transfection  in  GTM  and  NTM  cells,  the
construct containing A in position −2,388 possessed stronger
luciferase  activity  (122%  and  125.8%)  compared  to  the
construct containing G (100%; Figure 6, bar 1).
Deletion  of  putative  TF-binding  sites  3–6  caused  a
~10%–30% reduction of transcription activity in all cell types
tested (Figure 6). For some of the tested TF-binding sites the
effect was different in TM cells and other types of cells. For
example, deletion of cis-element nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) (−1,537 −1,527,
bars 2 in Figure 6) caused statistically significant reduction of
expression  (p<0.05)  by  ~25%  in  both  types  of  TM  cells
(Figure 6B), but did not alter it in HEK, SHY-5Y and Y79
cells (Figure 6A). Deletion of Sp1 binding site (−236 – 226,
bars 5) and E-twenty six (ETS) binding site (−182–174, bars
6 in Figure 6) caused only slight reduction of the promoter
activity in both types of TM cells, but caused statistically
significant reduction (p<0.01) in SHY-5Y cells (43.6 and 52%
of residual activity, respectively). In contrast, the deletion of
the cis-element 7 (Sp1 binding site −124–115) did not alter
the level of transcription in HEK, SHY-5Y and Y79 cells, but
slightly increased it in both types of TM cells (Figure 6B).
DISCUSSION
Our  data  show  that  CAV-2  expression  varies  between
individuals, whereas the level of CAV-1 expression is similar
(Figure 2). CAV-1 and CAV-2 have a similar perinuclear
punctate appearance in NTM and GTM cells (Figure 2A-F)
and are colocalized in dot-like structures (Figure 2D-F). The
results of intracellular colocalization of CAV-1 and CAV-2
in TM cells are similar to the data obtained previously in
adipose  tissues  and  other  tissue  types  [14,16].  As  was
suggested earlier, colocalization of CAV-1 and CAV-2 within
a single cell point to a different role they might play in cellular
physiology,  for  example  in  their  effect  on  intracellular
signaling through heterotrimeric G proteins [14].
We  used  two  commonly  known  glaucoma  promoting
agents,  i.e.TGF-β2  and  DEX  to  evaluate  their  effect  on
caveolins.TGF-β2  is  known  to  be  strongly  upregulated  in
aqueous humor of POAG patients [41], whereas DEX is a
glucocorticoid hormone which influences many aspects of
cell physiology. In addition, DEX is a widely used topical
ocular anti-inflammatory drug which exerts its therapeutic
effects by binding to the glucocorticoid receptor, leading to
the modulation of gene expression by trans- repression (i.e.,
regulating transcriptional regulators such as nuclear factor
NFκB [42]). However, it can also cause an increase in IOP
and subsequently, glaucoma [43].
Figure 3. Immunofluorescence localization of CAV-1 and CAV-2 in TM cells. CAV-1 (A, D, green). CAV-2 (B, E, red). NTM cells (A-C).
GTM cells (D-F). Polyclonal rabbit anti-CAV-1 and monoclonal mouse anti-CAV-2 were used for immunostaining. C and F: merged; blue
– DAPI staining. CAV-1 and CAV-2 immunoreactivity is identified as punctate staining with a predominant cytoplasmic localization (arrows).
In NTM cells CAV-1 was mainly found in the cytoplasm (A, arrows), while CAV-2 was present in cytoplasm, the perinuclear area as well as
in the cell membranes (B, arrowheads). In GTM cells CAV-1 and CAV-2 are colocalized in dot-like structures (arrows, D-F).
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2883In  experiments  with  immortalized  normal  and
glaucomatous  TM  cells  DEX  caused  considerably  higher
upregulation of CAV-1 expression in GTM-3 cells compared
to normal NTM-5 cells where the effect was moderate (Figure
4A).
The  level  of  CAV-1  phosphorylation  was  lower  in
glaucomatous  TMs  when  compared  to  normal  TM  cells
(Figure 5). This reduction in Tyr14 phosphorylation may have
a  significant  impact  on  cell  physiology,  because
phosphorylation of this tyrosine residue alters the properties
and intracellular localization of CAV-1 [38,39]. For example,
phosphorylation at Tyr14 is important for CAV-1 binding to
c-Src/Grb7 signaling complex [44]. CAV-1 undergoes Tyr14
phosphorylation and then serves as a scaffolding protein to
recruit SH2-domain containing proteins. This in turn may
increase the anchorage independent growth of cells [44].
Overall, our results show a reducing trend in caveolin
protein  expression,  including  reduced  phosphorylation,  in
cells and tissues derived from glaucoma patients. However
there was considerable variation among the different samples
and the cell lines used. This might be due to inherent genetic
diversity of the donor individuals as well as the fact that
transformed cell lines often do not mimic the original state
during in vitro experiments. Further studies are needed to
show whether this trend is linked to the pathogenicity of
POAG.
Interestingly, CAV-1 scaffolding domain (amino acids
81–100)  is  able  to  bind  α-synuclein  –  a  member  of  the
synuclein  family  implicated  in  the  process  of  neuro-
degeneration. Such physical interaction between CAV-1 and
α-synuclein may regulate α-synuclein-mediated actions on
cell  death,  processes  known  to  be  involved  in
synucleinopathies  [46-48].  However,  CAV-1  cannot  be
Figure 4. CAV-1 expression and secretion from NTM and GTM cells. A: DEX differentially induces CAV-1 expression in NTM-5 and GTM-3
cells after 24 and 48 h. Western blot probed with CAV-1 Ab. Below – the same blot was reprobed for actin. B: The first four lanes (1–4) for
NTM samples shown in A were scanned using KODAK MI Software. C: The next four lanes (5–8) for GTM samples were scanned. The
values indicated represent the means±SEM from four independent experiments. D and E: CAV-1 in cell extracts (CE; lanes 1–3 and 7–9) and
conditioned media (CM; lanes 4–6 and 10–12) of NTM-5 and GTM-3 cells. Lanes 1 and 7 – control cells; lanes 2 and 8 – cells were incubated
with 100 μM of DEX for 96 h; lanes 3 and 9 – cells incubated with 5 ng/ml of TGFβ2 for 48 h. TGFβ2 reduced CAV-1 expression to 85% in
NTM-5 cells (lane 3) and to 68% in GTM-3 cells (lane 9), whereas DEX did not affect CAV-1 expression after 96 h. Low level of CAV-1
secretion was observed from NTM cells (D, lanes 4–6) which was increased by DEX (lane 5). No expression was observed from GTM cells
(E, lanes10–12). F: Bands for NTM samples shown in D were scanned. G: Bands for GTM samples shown in E were scanned. The values
indicated represent the means±SEM from four independent experiments.
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2884considered as a protein indispensable for the internalization
of α-synuclein [49]. As has been shown earlier, both α- and
γ-synuclein  are  expressed  in  TM  cells  and  participate  in
glaucomatous  alterations  [31,32,45].  Further  studies  are
required to reveal whether CAV-1 – synuclein interactions
play a role in glaucomatous interactions in TM cells. Another
interesting aspect of the interaction between members of the
synuclein family and CAV-1 is that α- synuclein upregulates
expression  of  CAV-1  which  might  be  important  in  the
pathogenesis of neurodegenerative disorders [46-48].
Transcriptional  regulation  plays  an  important  role  in
determining the level of caveolin expression in normal and
disease states [21-24,49-51]. A bioinformatics search using
the software PROMO has shown, that the common sequence
variant (SNP) near CAV-1 [5] might create additional TF
binding sites in the upstream region of CAV-1. In the presence
of A at position −2,388 a homeobox is created with a sequence
of GTATT GTATT which may serve as a binding site for new
TFs [52-54]. The binding of HoxD9, HoxD10, and HNF-3A
has been predicted by analysis of this homeobox using the
software PROMO search. Binding of TFs to this homeobox
in turn might increase the level of gene expression detected in
LUC system (Figure 6). As shown previously, elevated levels
of CAV-1 expression may cause organ-specific abnormalities
[55]  and  exert  a  negative  effect  on  cell  physiology,  for
example  by  increasing  sensitivity  to  environmental  stress
[56].
Surprisingly, no significant variability in CAV-1 levels
in TM cells taken from five POAG patients and four controls
was found (Figure 2A). On the contrary, CAV-2 levels in these
cells  were  more  variable.  Since  information  about  the
polymorphisms  in  the  area  of  caveolins  genes  for  the
individuals whose TM cells were analyzed was unavailable,
it  was  difficult  to  explain  why  no  correlation  was  found
between  polymorphic  variation  in  the  CAV-1  promoter
(Figure 6) and the level of variability in the amount of CAV-1
in TM cells from patients (Figure 2A). One of the possible
explanations might be that all five patients had one allele, most
probably,  a  major  allele.  Alternatively,  although  the
polymorphic marker is located at a much longer distance from
CAV-2 than from CAV-1 and it is in the 3′-end of CAV-2, one
cannot  exclude  the  idea  that  this  marker  may  affect  the
expression level of CAV-2.
Another  interesting  finding  concerning  CAV-2  in
addition to variable level of its expression in samples from
different  patients  (Figure  2B)  is  the  presence  of  high
molecular  weight  aggregates  which  were  previously
characterized  as  heterooligomers  containing  CAV-1  and
CAV-2 [35].
Elevated  levels  of  CAV-1  and  CAV-2  have  been
associated with several forms of cancer, Alzheimer disease,
and other human diseases [57,58]. One of the mechanisms
underlying  their  involvement  in  pathology  is  linked  to
alterations of the cholesterol distribution in the cellular plasma
membrane  leading  to  the  dysregulation  of  cholesterol
homeostasis. A dysregulated expression of caveolin may also
be responsible for alterations in caveolin-dependent signal
transduction in cells [59].
Analysis of the effect of deletions and substitutions in the
upstream region of CAV-1 on LUC expression demonstrated
that  the  substitution  of  G  with  A  (SNP  described  by
Thorleifsson and coauthors [5]) as well as deletions of several
putative  TF-binding  sites  affected  gene  expression.  The
presence of A in position −2,388 ensured a higher level of
promoter activity than G in all cell types tested (Figure 6). The
deletion of putative TF-binding sites affected transcriptional
activity in a cell-type specific manner.
Deletion of putative TF-binding sites 3–6 for HNF-3,
Pou-IV,  Sp1  (−236  −226),  and  Ets  caused  a  ~10%–30%
reduction  of  transcription  activity  in  all  cell  types  tested
(Figure 6, bars 3–6). Deletion of cis-element 7 (Sp1 −124–
115) did not alter the level of transcription in HEK, SHSY-5Y,
Figure 5. Phosphorylation of Tyr14 in CAV-1 in NTM-5 and GTM-3
cells. A: NTM and GTM cell lysates were immunoprecipitated by
polyclonal antirabbit Ab against CAV-1 and the precipitate was
suspended in a 2× loading buffer (ABCam Immunoprecipitation
Protocol) and western blotted with monoclonal antimouse CAV-1
Ab. B: The same blot was stripped and reprobed with monoclonal
antimouse pTyr14-CAV-1 antibody. C: Lanes shown in A and B
were scanned using KODAK MI Software. The amount of non-
phosphorylated CAV-1 is similar in NTM-5 and GTM-3 samples
(A), while the amount of CAV-1 phosphorylated at Tyr14 (P-Tyr14-
CAV-1) is 2.3 times lower in GTM-3 cells. Arrowhead indicates
heavy chain immunoglobulins. The values indicated represent mean
±SEM from four independent experiments.
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2885and Y79 cells and slightly increased it in both types of TM
cells (Figure 6B). In NTM cells the effect of deletion of TF-
binding sites was more pronounced than in GTM cells.
In summary, the data presented here demonstrate new
mechanisms of CAV-1 and CAV-2 regulation which may play
an important role in glaucomatous alterations in TM cells. A
recently described A/G polymorphism in the CAV-1 promoter
[5] was found to affect the level of expression directed by the
CAV-1 upstream region in LUC system. Another interesting
finding is a significant level of variability of CAV-2 expression
in TM cells from different individuals, compared to a similar
level of CAV-1 expression. Further studies are required to
Figure 6. Effect of CAV-1 promoter modification on the expression
level  in  LUC  system.  Cells  were  transfected  with  1  µg  pGL3
promoterless LUC reporter plasmids inserted with intact or modified
2,465 bases CAV-1 promoter region (pGL3-CAV-1 promoterA or
pGL3-CAV-1promoterG). LUC activity was averaged. The SEM is
indicated by the error bars. One – ratio of activity of construct with
A  to  activity  of  construct  with  G  in  position  −2,388  of  CAV-1
promoter; 2 – 8 putative cis-elements were deleted from CAV-1
promoter and the activity of the construct with deleted sequence was
expressed in percentage to the unmodified construct. The following
putative TF-binding sites were deleted: 2– NFκB (position −1537
−1527); 3 - HNF-3/Fkh homolog (position - 889 −882); 4 - POU-IV
position (−807 −800); 5 – Sp-1 (position −236 −226); 6 – Ets (−182–
174); 7 - SP-1 (position −124–115); 8– NFkB (position −40 −28).
Other details are presented in Table 2. A: The effect of CAV-1
promoter modification on LUC activity in HEK-293, SH-SY5Y and
Y79 cells. B: The effect of CAV-1 promoter modification on LUC
activity in NTM-5 and GTM-3 cells.
reveal whether the variability in CAV-2 expression is relevant
to glaucoma pathogenesis.
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